{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T20:54:41Z","timestamp":1770584081595,"version":"3.49.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.1513\/annalsats.202308-735rl","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T09:28:40Z","timestamp":1701250120000},"page":"360-362","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":4,"title":["Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor\/Tezacaftor\/Ivacaftor"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7960","authenticated-orcid":false,"given":"David","family":"Nichols","sequence":"first","affiliation":[{"name":"University of Washington Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Gifford","sequence":"additional","affiliation":[{"name":"Case Western Reserve University Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Russell","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Odem-Davis","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Young","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Amaro-Galvez","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center Tyler, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Billings","sequence":"additional","affiliation":[{"name":"University of Minnesota Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zubin","family":"Mukadam","sequence":"additional","affiliation":[{"name":"Wayne State University Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[{"name":"University of Washington Seattle, Washington"},{"name":"TDN Coordinating Center Seattle Children\u2019s Research Institute Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2026012203141080500_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012203141080500_bib2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: the SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203141080500_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012203141080500_bib4","author":"Cystic Fibrosis Foundation Patient Registry 2021 annual data report","year":"2021"},{"key":"2026012203141080500_bib5","author":"The HERO-2 Study"},{"key":"2026012203141080500_bib6","author":"CF Storm: clearing the air","year":"."},{"key":"2026012203141080500_bib7","first-page":"295","article-title":"Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS","volume":"48","author":"Goss","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2026012203141080500_bib8","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/2\/360\/66018255\/annalsats_21_2_360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/2\/360\/66018255\/annalsats_21_2_360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:15:11Z","timestamp":1769069711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/2\/360\/8382093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202308-735rl","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"2024-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}